Vapotherm Stock - background check on a delisted small cap

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 17:03 CET. Details in the imprint.

Vapotherm (US92206C1099) was once a small US medical technology stock focused on advanced respiratory care. With no current listing on a major exchange and no fresh investor relations updates, the company now invites mainly a background look rather than live trading analysis.

Why no fresh Friday hook exists

Vapotherm’s official investor relations page currently shows only archived materials and older SEC filings, with no dated press release or corporate action in the last 24 hours. Historic announcements center on funding steps, restructuring and earlier business updates.

The former ticker VAPO no longer appears with a live price feed on major quote platforms, which confirms that a real-time trading hook or weekly share-price review is not possible. Instead, only legacy quote snapshots and past chart data remain available to market observers.

What past filings reveal

In previous years Vapotherm Inc. described itself as a medical technology company developing and commercializing proprietary high-velocity nasal insufflation systems for patients with respiratory distress. Historic SEC filings outlined revenue from critical-care hospitals and emergency departments.

Those filings also documented recurring net losses, high operating expenses and a need for external capital, a pattern typical of small medtech names. At times the company disclosed debt restructurings and financings designed to extend its cash runway while it sought broader commercial adoption.

How Vapotherm once traded

During its Nasdaq period under the symbol VAPO, Vapotherm shares saw phases of strong volatility, particularly around quarterly results and funding announcements. Trading volumes were often modest, reflecting a narrow shareholder base and limited institutional coverage.

Over time, continued losses and financing pressure weighed on the equity story. As is common with such micro caps, liquidity thinned further, spreads widened and daily trading became sporadic before the listing ultimately ceased.

The sector backdrop today

Vapotherm’s historic peer group includes niche respiratory-care and ventilation technology providers, many of which still trade publicly and benefit from aging populations and respiratory disease trends. Larger diversified medtechs dominate the segment with broad product portfolios.

Current sector discussions focus on hospital capital spending, reimbursement pressure and post-pandemic normalization of respiratory equipment demand. Against this broadly dynamic backdrop, Vapotherm’s absence from trading screens stands out as a reminder of the risks smaller innovators face.

The product behind the stock

Vapotherm’s best-known product line has been the Precision Flow system, a high-velocity nasal insufflation platform intended to deliver heated, humidified oxygen-rich gas to patients with respiratory distress. The systems were marketed primarily to hospitals and intensive-care environments.

Where the stock trades today

Vapotherm stock is not currently quoted on a major exchange, and no reliable real-time price, market capitalization or trading venue can be verified at this time.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.